Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study-Reference-Cited by-同舟云学术

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Published:2020-07-21 Issue:3 Volume:72 Page:892-905
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Ratziu Vlad¹,Sanyal Arun²,Harrison Stephen A.³,Wong Vincent Wai‐Sun⁴^ORCID,Francque Sven⁵,Goodman Zachary⁶,Aithal Guruprasad P.⁷,Kowdley Kris V.⁸,Seyedkazemi Star⁹,Fischer Laurent⁹,Loomba Rohit¹⁰¹¹,Abdelmalek Manal F.¹²,Tacke Frank¹³¹⁴^ORCID

Affiliation:

1. Hôpital Pitié Salpêtrière and Sorbonne Université Paris France

2. Department of Gastroenterology Virginia Commonwealth University Richmond VA

3. Pinnacle Clinical Research San Antonio TX

4. Department of Medicine and Therapeutics Chinese University of Hong Kong Hong Kong People's Republic of China

5. Gastroenterology and Hepatology Antwerp University Hospital University of Antwerp Antwerp Belgium

6. Center for Liver Diseases Inova Fairfax Medical Campus Falls Church VA

7. NIHR Nottingham Biomedical Research Centre Nottingham University Hospitals NHS Trust and University of Nottingham Nottingham UK

8. Liver Care Network Swedish Medical Center Seattle WA

9. Allergan plc South San Francisco CA

10. Division of Gastroenterology Department of Medicine University of California San Diego, La Jolla CA

11. NAFLD Research Center Department of Medicine University of California San Diego, La Jolla CA

12. Division of Gastroenterology & Hepatology Department of Medicine Duke University Durham NC

13. Department of Medicine III University Hospital Aachen Aachen Germany

14. Department of Gastroenterology & Hepatology Charité University Medical Center Berlin Berlin Germany

Funder

Allergan

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31108

Reference27 articles.

1. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

2. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

3. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma

4. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

5. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Jiawei Taohe Chengqi Decoction attenuates CCl4 induced hepatic fibrosis by inhibiting HSCs activation via TGF-β1/CUGBP1 and IFN-γ/Smad7 pathway;Phytomedicine;2024-10

3. Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation;Redox Biology;2024-10

4. Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics;Livers;2024-09-13

5. Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?;Digestive and Liver Disease;2024-09